

Antibiotic-free Microbial Expression and Genetic Systems

A world leading health company is seeking novel **antibiotic-free microbial expression systems** for production of a wide range of biologics including recombinant proteins, peptides, antigens, Fc-fusion proteins, and monoclonal antibodies. Additionally, the team is looking for partners and/or technologies to support **removal of AMR genes from bacterial genomes** through genetic modification.



Approaches of Interest:

- Bacterial or cell-based expression systems that are cost-effective, produce a high biologic yield and have scalable manufacturing capability are of interest
- *Escherichia coli* systems are of highest interest, however Gram-positive systems from manufacturable strains will be considered
- Host strains will ideally be low or free from endotoxins and systems that have control of contamination and genetic drift are preferred
- Technologies must be robust (e.g., replication, genetic stability, inducible protein expression, ease of purification) and without requirements for rare or expensive components
- Contamination and genetic drift will ideally be controlled

Out of Scope:

- Plasmid selection relying on toxin/anti-toxin maintenance
- CHO and other mammalian cell lines (NS0, Sp2/0, BHK, Murine C127, HeLa, HEK293, Sf9, MCF-7)

Developmental Stages of Interest:

- Ready-to-use expression systems are of priority; however systems with evidence of inducible expression will be considered





Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. Please be aware that regional restrictions apply to this campaign – submissions must originate from regions that are free, low risk, or not affected with foreign animal diseases. Submissions from US and western Europe are prioritised, but a full list of preferred regions is found [here](#).

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations for further development of the expression system. An exclusive license for commercial use is preferred.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **4th December 2024 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk